Our Deals

Deep 6 AI Acquired by Tempus 

Sengenics, a Portfolio Company of Summa Equity, Acquired by Standard BioTools

Bio-Techne Divested Assets of Its Subsidiary, Atlanta Biologicals, to GeminiBio

Anju Software Acquired by Valsoft Corporation to Grow eClinical and Commercialization Capabilities

Pinnacle Clinical Research Acquired The Cognitive and Research Center of New Jersey to Expand Clinical Trial Site Network

Pinnacle Clinical Research Acquires Kerwin Medical Center to Bolster Clinical Trial Site Network

BBI Solutions, a Portfolio Company of Novo Holdings, Acquired IBEX Technologies Inc. to Bolster Recombinant Protein Offering

Myonex Acquired Creapharm's Clinical & Commercial Packaging and Bioservices Business Units to Expand Clinical Trial Supply Services and Gain of Foothold in Europe

Myonex Acquired SaveWay Compounding Pharmacy to Expand and Bolster its Clinical Trial Services Across the US

Calyx has divested its 'Enterprise Technology' Division to Ennov, to Enhance Ennov’s portfolio of eClinical and eRegulatory Software Solutions

physIQ Acquired by Prolaio to Enhance its Next-Gen Connected Heart Care Technology for Clinical Care and Research

Continuum Clinical, a BC Worldwide company, Acquired by Spectrum Science, a Portfolio Company of Knox Lane, to Bolster Patient Engagement Capabilities

Yecuris Corporation Acquired by Janvier Group to Expand Preclinical Service Offering Internationally

Modular Devices, a Portfolio Company of O2 Investment Partners, Partners with Flow Clean Rooms and Supply to Bolster Existing Clean Room Manufacturing Capabilities and Expand Overall Offering

Alpha IRB Acquired by Sabai Global, a Portfolio Company of Thompson Street Capital, to Expand IRB Capabilities

Versiti Acquired Pearl Pathways to Expand Clinical Trial Services Capabilities

VaxTRIALS Acquired by Emmes, a portfolio company of New Mountain Capital, to Expand Vaccine and Clinical Trial Site Capabilities

Grant Avenue Capital Recapitalizes CREO

Monroe Biomedical Research Acquired by New Harbor Capital in a First Step to Build-out a Clinical Research Site Platform

SSI Strategy, a Portfolio Company of Amulet Capital Partners, Acquired NDA Group AB to Bolster Regulatory Affairs Consulting Capabilities and Expand Into the EU